{"url_path":"/sec/ptpi/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-060359-index.html","accession_number":"0001104659-26-060359","cik":"0001815903","ticker":"PTPI","issuer_name":"Petros Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-060359-index.html","primary_entity_key":"0001815903","primary_entity_name":"Petros Pharmaceuticals, Inc."},"word_count":42,"has_tables":true,"body_markdown":"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.\n\nThere were no unregistered sales of the Company’s equity securities during the three months ended March 31, 2026, other than those previously reported in a Current Report on Form 8-K.\n\n​"}